Ebola vaccines: we have options

Affiliations

¹ Vaccine and Infectious Disease Organization-International Vaccine Centre (VIDO-InterVac), University of Saskatchewan, Saskatoon, SK S7N 5E3, Canada. Electronic address: darryl.falzarano@usask.ca.

Comment

Darryl Falzarano. Lancet Infect Dis. 2016 Mar.

. 2016 Mar;16(3):267-8.

doi: 10.1016/S1473-3099(15)00534-4. Epub 2015 Dec 23.

¹ Vaccine and Infectious Disease Organization-International Vaccine Centre (VIDO-InterVac), University of Saskatchewan, Saskatoon, SK S7N 5E3, Canada. Electronic address: darryl.falzarano@usask.ca.

No abstract available

Comment on

Safety and immunogenicity of a chimpanzee adenovirus-vectored Ebola vaccine in healthy adults: a randomised, double-blind, placebo-controlled, dose-finding, phase 1/2a study.
De Santis O, Audran R, Pothin E, Warpelin-Decrausaz L, Vallotton L, Wuerzner G, Cochet C, Estoppey D, Steiner-Monard V, Lonchampt S, Thierry AC, Mayor C, Bailer RT, Mbaya OT, Zhou Y, Ploquin A, Sullivan NJ, Graham BS, Roman F, De Ryck I, Ballou WR, Kieny MP, Moorthy V, Spertini F, Genton B. De Santis O, et al. Lancet Infect Dis. 2016 Mar;16(3):311-20. doi: 10.1016/S1473-3099(15)00486-7. Epub 2015 Dec 23. Lancet Infect Dis. 2016. PMID: 26725450 Clinical Trial.